Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marie Jarbath

Physician Assistant, Surgical Webster, TX Physician Assistant

NPI 1164425195 CMS profile 10835900

17448 Highway 3, Ste 136, Webster, TX 77598

Open in the dashboard

General payments

$10,363

302 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marie Jarbath of Webster, TX is reported in the CMS Open Payments database as having received $10,363 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,583 49
2024 General $3,422 59
2023 General $2,256 58
2022 General $1,453 61
2021 General $1,647 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marie Jarbath
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Marie Jarbath were reported at $1,583. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Marie Jarbath Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,647 $111 $36–$285 $132
2022 $1,453 $126 $44–$350 $149
2023 $2,256 $137 $47–$355 $160
2024 $3,422 $146 $49–$384 $164
2025 $1,583 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Saluda Medical Americas, Inc. $2,013 20 payments
  2. TerSera Therapeutics LLC $1,053 48 payments
  3. Nevro Corp. $1,011 25 payments
  4. Boston Scientific Corporation $754 9 payments
  5. Collegium Pharmaceutical, Inc. $723 35 payments
  6. Medtronic, Inc. $693 11 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $488 17 payments
  8. AbbVie, Inc. $430 27 payments
  9. Inspire Medical Systems, Inc. $292 4 payments
  10. Scilex Pharmaceuticals Inc. $243 12 payments
  11. Other $2,663 94 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,726 294 payments
  2. Travel and Lodging $1,592 7 payments
  3. Education $45 1 payment
Products named General payments · program years 2021–2025
  1. Evoke $1,988 19 payments
  2. Prialt $945 42 payments
  3. SYNCHROMEDII $630 8 payments
  4. Omnia $550 9 payments
  5. RELISTOR $488 17 payments
  6. Senza $461 16 payments
  7. BELBUCA $340 17 payments
  8. XTAMPZA $317 15 payments
  9. UBRELVY $317 21 payments
  10. INSPIRE $292 4 payments
  11. Other $4,214 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,015

Median for Physician Assistant: 241

Drug cost

$90,742

Median for Physician Assistant: $4,110

Branded share of claims

28.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 70 $47,085
Buprenorphine Generic 64 $14,936
Acetaminophen-Codeine Acetaminophen With Codeine Brand 366 $7,090
Tramadol Hcl Generic 551 $6,053
Tramadol Hcl Er Tramadol Hcl Brand 98 $4,773
Pregabalin Generic 175 $3,567
Gabapentin Generic 119 $1,809
Cyclobenzaprine Hcl Generic 97 $1,151
Tizanidine Hcl Generic 53 $572
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 43 $569

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $242
$242 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $90
$90 70 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $89
$89 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $70
$70 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record